Sentiment Trading

Forte Biosciences Inc.’s stock surged 25% after a Phase 1b trial of its celiac disease treatment, FB102, showed positive results, setting the stage for a Phase 2 trial.

Forte Biosciences, Inc. is a biotech company pioneering innovative cancer treatments, with a mission to change the lives of patients and make significant contributions to the field of cancer treatment.